We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Biosignatures Distinguish Between Fatal Lung Diseases

By LabMedica International staff writers
Posted on 29 May 2012
In the blood of tuberculosis and sarcoidosis patients a complete gene and micro-ribonucleic acid (miRNA) expression profiles have been created together with important inflammatory mediators. More...


It is almost impossible to distinguish between tuberculosis (TB) and sarcoidosis with just a single signature, therefore a set of different biosignatures is better suited for distinguishing between diseased and healthy individuals and, in a further step, between the specific diseases.

Scientists at the Max Planck Institute for Infection Biology (Berlin, Germany) using gene and miRNA expression in blood cells and inflammatory mediators in serum, selected sets of markers characteristic for tuberculosis and sarcoidosis patients. Although both diseases primarily damage the lungs and produce similar symptoms, they have very different causes as TB is caused by an infection with the bacteria Mycobacterium tuberculosis, while sarcoidosis is not contagious.

The two diseases are not only similar clinically but their biosignatures have a number of elements in common. Compared to healthy individuals, most genes in sarcoidosis and tuberculosis patients are regulated in a similar way. The results obtained by the Berlin investigators show that modified biomarkers can be traced back to processes that occur not only in one specific disease, such as immune responses. The immune response therefore draws on the same basic elements in different clinical pictures, and only a few of these elements are specific to a particular disease. These commonalities also reveal to scientists a lot about the general causes and mechanisms underlying many diseases.

In total, around 150 miRNAs shared by both diseases differed from healthy individuals. Only four miRNAs are suitable for distinguishing TB and sarcoidosis patients. The overlap is less pronounced in the profile of inflammatory substances in the blood: while only one of these cytokines is modified equally in TB and sarcoidosis compared to healthy individuals, twelve of these signal mediators are suitable for distinguishing between the two diseases.

A single biosignature is therefore not enough to distinguish between healthy and diseased individuals, and to distinguish between different diseases with a similar clinical phenotype. Although the combination of many genes increases specificity and sensitivity in distinguishing between healthy and diseased individuals, it automatically leads to a lower specificity compared to other clinical pictures.

Stefan H.E. Kaufmann, PhD, a professor at the Max Planck Institute, said, "Of approximately 13,000 genes whose expression differs, depending on whether the individual is healthy or diseased, approximately 9,000 genes are expressed in the same way in both diseases. Only 700 genes differ in their expression between tuberculosis and sarcoidosis patients - but these can be used to unequivocally identify the two diseases."

Related Links:

Max Planck Institute for Infection Biology



Gold Member
Troponin T QC
Troponin T Quality Control
Serological Pipet Controller
PIPETBOY GENIUS
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
New
Hand-Held Immunofluorescence Analyzer
WS-Si1500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.